SILK ROAD MEDICAL INC (SILK)

US82710M1009 - Common Stock

27.49  -0.01 (-0.04%)

After market: 27.49 0 (0%)

Fundamental Rating

3

Taking everything into account, SILK scores 3 out of 10 in our fundamental rating. SILK was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While SILK seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SILK is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SILK has reported negative net income.
In the past year SILK has reported a negative cash flow from operations.
SILK had negative earnings in each of the past 5 years.
In the past 5 years SILK always reported negative operating cash flow.

1.2 Ratios

SILK has a Return On Assets of -20.96%. This is comparable to the rest of the industry: SILK outperforms 51.87% of its industry peers.
SILK has a Return On Equity of -36.55%. This is comparable to the rest of the industry: SILK outperforms 54.01% of its industry peers.
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROIC N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SILK's Gross Margin of 74.28% is amongst the best of the industry. SILK outperforms 85.03% of its industry peers.
SILK's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SILK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%

More info and screens

5

2. Health

2.1 Basic Checks

SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SILK has more shares outstanding
Compared to 5 years ago, SILK has more shares outstanding
The debt/assets ratio for SILK is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 4.49 indicates that SILK is not in any danger for bankruptcy at the moment.
The Altman-Z score of SILK (4.49) is better than 72.73% of its industry peers.
SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
SILK has a worse Debt to Equity ratio (0.49) than 64.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC8.47%

2.3 Liquidity

A Current Ratio of 7.63 indicates that SILK has no problem at all paying its short term obligations.
SILK has a better Current ratio (7.63) than 85.56% of its industry peers.
A Quick Ratio of 6.69 indicates that SILK has no problem at all paying its short term obligations.
SILK's Quick ratio of 6.69 is amongst the best of the industry. SILK outperforms 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 6.69

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SILK have decreased by -2.13% in the last year.
SILK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.54%.
Measured over the past years, SILK shows a very strong growth in Revenue. The Revenue has been growing by 38.63% on average per year.
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%

3.2 Future

Based on estimates for the next years, SILK will show a small growth in Earnings Per Share. The EPS will grow by 3.87% on average per year.
Based on estimates for the next years, SILK will show a quite strong growth in Revenue. The Revenue will grow by 13.50% on average per year.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SILK. In the last year negative earnings were reported.
Also next year SILK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SILK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILK ROAD MEDICAL INC

NASDAQ:SILK (9/16/2024, 8:00:02 PM)

After market: 27.49 0 (0%)

27.49

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-06 2024-11-06/amc
Inst Owners3.3%
Inst Owner Change-96.48%
Ins Owners28.49%
Ins Owner Change-19.36%
Market Cap1.12B
Analysts49.23
Price Target22.54 (-18.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-9.6%
Max EPS beat(2)12.31%
EPS beat(4)3
Avg EPS beat(4)8.54%
Min EPS beat(4)-9.6%
Max EPS beat(4)23.2%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)7
Avg EPS beat(12)1.66%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)1.28%
Max Revenue beat(2)6.4%
Revenue beat(4)3
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)10.41%
Revenue beat(8)6
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)2.91%
Revenue beat(16)12
Avg Revenue beat(16)2.27%
PT rev (1m)-2.14%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)-2.69%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.83
P/FCF N/A
P/OCF N/A
P/B 7.22
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS4.71
BVpS3.81
TBVpS3.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.28%
FCFM N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.1%
Cap/Sales 1.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 6.69
Altman-Z 4.49
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)251.08%
Cap/Depr(5y)187.13%
Cap/Sales(3y)3.05%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
EBIT growth 1Y-13.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.12%
EBIT Next 3Y19.7%
EBIT Next 5YN/A
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.14%
OCF growth 3YN/A
OCF growth 5YN/A